Found: 5
Select item for more details and to access through your institution.
Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study.
- Published in:
- Helicobacter, 2021, v. 26, n. 2, p. 1, doi. 10.1111/hel.12776
- By:
- Publication type:
- Article
Effect of probiotics during vonoprazan‐containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial.
- Published in:
- Helicobacter, 2020, v. 25, n. 3, p. 1, doi. 10.1111/hel.12690
- By:
- Publication type:
- Article
Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-020-80802-3
- By:
- Publication type:
- Article
Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS).
- Published in:
- BMC Gastroenterology, 2012, v. 12, n. 1, p. 42, doi. 10.1186/1471-230X-12-42
- By:
- Publication type:
- Article
Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study.
- Published in:
- Journal of Gastroenterology, 2023, v. 58, n. 3, p. 196, doi. 10.1007/s00535-022-01942-z
- By:
- Publication type:
- Article